Keros Therapeutics (NASDAQ:KROS) Shares Down 2.7% Following Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS) shares dropped 2.7% on Tuesday after Truist Financial lowered their price target on the stock from $100.00 to $43.00. Truist Financial currently has a buy rating on the stock. Keros Therapeutics traded as low as $16.63 and last traded at $16.65. Approximately 211,223 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 487,966 shares. The stock had previously closed at $17.12.

A number of other analysts have also weighed in on the stock. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Guggenheim lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, December 16th. Wells Fargo & Company upped their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Finally, Wedbush restated an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC raised its stake in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the last quarter. Alkeon Capital Management LLC raised its position in Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. lifted its holdings in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares during the period. Point72 Asset Management L.P. boosted its position in Keros Therapeutics by 155.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Finally, Holocene Advisors LP grew its stake in shares of Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Stock Performance

The business’s 50 day moving average price is $54.10 and its 200 day moving average price is $51.40. The firm has a market cap of $674.44 million, a price-to-earnings ratio of -3.20 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.33) EPS. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.